AS 109

Drug Profile

AS 109

Alternative Names: Pepscan

Latest Information Update: 19 Jul 2012

Price : $50

At a glance

  • Originator Antisoma
  • Class Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 11 Jan 2012 Discontinued - Clinical-Phase-Unknown for Breast cancer in Japan (unspecified route)
  • 08 Nov 2002 AS 109 is available for licensing (
  • 19 Aug 2002 No development reported - Phase I/II for Breast cancer (diagnosis) in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top